RheumaFinder announces investment by Novalis Biotech to revolutionize care for patients with rheumatic diseases

RheumaFinder is at the forefront of revolutionizing rheumatology medical imaging with cutting-edge AI technology. Given the propensity for diagnostic delays and underdiagnosis in rheumatic diseases, RheumaFinder addresses this critical clinical need head-on.

The company’s innovative engine diligently analyzes standard medical images to detect early signs of structural damage in joints. This early detection tool serves as an invaluable aid to radiologists and rheumatologists, contributing to sustainable healthc are practices by providing earlier and more accurate diagnoses of rheumatic diseases . This ensures that patients who may be unaware of their condition can receive timely and appropriate treatment, streamlining the healthcare pathway.

RheumaFinder’s ultimate goal is to facilitate timely interventions for numerous patients, thereby safeguarding joint health and significantly improving quality of life.

With this new infusion of capital, RheumaFinder aims to further develop and clinically validate their AI software solution. Additionally, the company plans to initiate conversations with external parties such as hospitals, clinics and pharmaceutical companies for potential collaborations, enhancement of clinical trials and beta software testing opportunities.

Wim Van Criekinge, Co Founder and Managing Director of Novalis, praised RheumaFinder: "Their exceptional team and founders' expertise deeply impressed us. We are aligned with their vision of a lean AI engine that addresses the currently unmet clinical need for early detection of rheumatic diseases. We're confident that their technology's m ultimodal sensitivity has potential for broad market applications and will make RheumaFinder a standout in the maturing medical imaging AI sector."

Nicolaas Fosselle, CEO of RheumaFinder, commented on the collaboration: "Novalis has been an invaluable addition to our funding process, bringing not just financial support but also a synergistic ecosystem to bolster our ambitious growth. Our interactions with Kjell Mortie r and Wim Van Criekinge at Novalis during late fall solidified our initial impressions, leading to a timely and fruitful agreement. Novalis's commitment to translate extensive scientific and clinical research towards commercialization alig ns perfectly with our mission to address the societal and patient challenges posed by late or underdiagnosed rheumatic conditions."